This first-in-human study will evaluate the safety and tolerability of ADX-626 in healthy participants. The study will also look at how ADX-626 interacts with the human body (the pharmacokinetics and pharmacodynamics of ADX-626).
Eligibility
Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Key Inclusion Criteria:
* Age 18 to 45 years at the time of informed consent
* Males or women of non-childbearing potential (WONCBP)
* Willing to comply with all study requirements while participating
* Suitable venous access for blood sampling.
* Body weight ≥ 50 kg and a body mass index (BMI) ≤25 kg/m2
* Normal laboratory results including liver enzymes, hemoglobin, platelet count, and coagulation parameters
* Willing to use acceptable contraception methods if applicable
Key Exclusion Criteria:
* Significant medical condition such as hypertension, diabetes, cardiovascular disease, or cancer
* History of bleeding or coagulation disorders, prior instances of major bleeding, or a family history of bleeding disorders.
* Current infection
* Participation in an interventional drug study within the last 90 days
Primary outcome measure(s)
Safety of ADX-626 in Healthy Participants — Day 1 to Day 365 Incidence, relationship and severity of adverse events and serious adverse events
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.